Predictive significance of thyroid transcription factor-1 expression in patients with non‑squamous non-small cell lung cancer with wild-type epidermal growth factor receptor treated with erlotinib

  • Authors:
    • Yoshiro Nakahara
    • Yukio Hosomi
    • Makoto Saito
    • Masumi Ogawa
    • Tsunekazu Hishima
    • Tatsuru Okamura
    • Jiichiro Sasaki
    • Noriyuki Masuda
  • View Affiliations

  • Published online on: April 21, 2016     https://doi.org/10.3892/mco.2016.870
  • Pages: 14-18
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Little is known on the efficacy of erlotinib treatment in patients expressing wild-type epidermal growth factor receptor (EGFR). This study is a retrospective review of patients with non‑squamous, non‑small‑cell lung cancer (NS‑NSCLC) and wild‑type EGFR who were treated with erlotinib alone as second- or later‑line chemotherapy at the Tokyo Metropolitan Cancer and Infectious Diseases Center of Komagome Hospital (Tokyo, Japan) between December, 2008 and December, 2013. Thyroid transcription factor‑1 (TTF-1) was immunohistochemically analyzed in 26 of 53 patients, among whom 20 (77%) and 6 (23%) were considered as TTF‑1‑positive and -negative, respectively. The median follow‑up of these 26 patients was 133 days (range, 26‑873 days). The time‑to‑treatment failure was significantly longer in TTF‑1‑positive compared with that in TTF‑1‑negative patients [49.5 vs. 20.0 days; 95% confidence interval (CI): 28‑90 vs. 14‑74 days, respectively; P=0.01]. The overall survival was significantly better for TTF‑1‑positive (227 days; 95% CI: 110‑366 days) compared with TTF-1-negative patients (P=0.0002). Therefore, the expression of TTF-1 may serve as a useful tool for predicting the efficacy of erlotinib in patients with NS-NSCLC expressing wild‑type EGFR.
View Figures
View References

Related Articles

Journal Cover

July 2016
Volume 5 Issue 1

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Nakahara, Y., Hosomi, Y., Saito, M., Ogawa, M., Hishima, T., Okamura, T. ... Masuda, N. (2016). Predictive significance of thyroid transcription factor-1 expression in patients with non‑squamous non-small cell lung cancer with wild-type epidermal growth factor receptor treated with erlotinib. Molecular and Clinical Oncology, 5, 14-18. https://doi.org/10.3892/mco.2016.870
MLA
Nakahara, Y., Hosomi, Y., Saito, M., Ogawa, M., Hishima, T., Okamura, T., Sasaki, J., Masuda, N."Predictive significance of thyroid transcription factor-1 expression in patients with non‑squamous non-small cell lung cancer with wild-type epidermal growth factor receptor treated with erlotinib". Molecular and Clinical Oncology 5.1 (2016): 14-18.
Chicago
Nakahara, Y., Hosomi, Y., Saito, M., Ogawa, M., Hishima, T., Okamura, T., Sasaki, J., Masuda, N."Predictive significance of thyroid transcription factor-1 expression in patients with non‑squamous non-small cell lung cancer with wild-type epidermal growth factor receptor treated with erlotinib". Molecular and Clinical Oncology 5, no. 1 (2016): 14-18. https://doi.org/10.3892/mco.2016.870